Fuller & Thaler Asset Management, Inc. Exelixis, Inc. Transaction History
Fuller & Thaler Asset Management, Inc.
- $25.7 Billion
- Q4 2024
A detailed history of Fuller & Thaler Asset Management, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Fuller & Thaler Asset Management, Inc. holds 7,630,940 shares of EXEL stock, worth $292 Million. This represents 0.99% of its overall portfolio holdings.
Number of Shares
7,630,940
Previous 6,922,628
10.23%
Holding current value
$292 Million
Previous $180 Million
41.45%
% of portfolio
0.99%
Previous 0.72%
Shares
24 transactions
Others Institutions Holding EXEL
# of Institutions
566Shares Held
251MCall Options Held
1.45MPut Options Held
1.13M-
Black Rock Inc. New York, NY33.5MShares$1.28 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.13 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$897 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$586 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$437 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.3B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...